MAPT and Alzheimer disease: AD-related amyloid-β (Aβ) and tau pathologies are detectable and monitored in cerebrospinal fluid (CSF) and using positron emission tomography (PET) with high accuracy; however, their broad implementation is impractical in routine clinical care practices [3, 4].